| Year |
Citation |
Score |
| 2024 |
Roper N, El Meskini R, Maity T, Atkinson D, Day A, Pate N, Cultraro CM, Pack S, Zgonc V, Weaver Ohler Z, Guha U. Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. Cancer Research Communications. 4: 337-348. PMID 38276867 DOI: 10.1158/2767-9764.CRC-23-0321 |
0.308 |
|
| 2021 |
Venugopalan A, Lynberg M, Cultraro CM, Nguyen KDP, Zhang X, Waris M, Dayal N, Abebe A, Maity TK, Guha U. SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma. Oncogene. PMID 33850265 DOI: 10.1038/s41388-021-01764-y |
0.331 |
|
| 2020 |
Venugopalan A, Nguyen K, Lynberg M, Maity T, Qi Y, Roper N, Cultraro C, Chan K, Misra V, Thorkell A, Zhang X, Crooks D, Linehan WM, Lane AN, Guha U. Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR – Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.00602 |
0.331 |
|
| 2019 |
Roper N, Gao S, Maity TK, Banday AR, Zhang X, Venugopalan A, Cultraro CM, Patidar R, Sindiri S, Brown AL, Goncearenco A, Panchenko AR, Biswas R, Thomas A, Rajan A, et al. APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors. Cell Reports. 26: 2651-2666.e6. PMID 30840888 DOI: 10.1016/J.Celrep.2019.02.028 |
0.389 |
|
| 2019 |
Zhang X, Nguyen KD, Rudnick P, Roper N, Kawaler E, Maity TK, Awasthi S, Gao S, Biswas R, Venugopalan A, Cultraro CM, Fenyö D, Guha U. Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V. Molecular & Cellular Proteomics : McP. PMID 30617155 DOI: 10.1074/Mcp.Ra118.001266 |
0.372 |
|
| 2019 |
Roper N, Brown A, Sindiri S, Cultraro CM, Gao S, Kim C, Hoang CD, Maity TK, Akoth E, Rajan A, Venugopalan AK, Trindade C, Wei JS, Panchenko A, Hewitt SM, et al. Clonal evolution and osimertinib resistance mechanisms identified by whole exome and transcriptome sequencing in EGFR mutant NSCLC. Journal of Clinical Oncology. 37: 9049-9049. DOI: 10.1200/Jco.2019.37.15_Suppl.9049 |
0.33 |
|
| 2019 |
Xhang X, Nguyen KDP, Rudnick P, Roper N, Kawaler E, Maity TK, Awasthi S, Gao S, Biswas R, Venugopalan A, Cultraro C, Fenyo D, Guha U. Abstract 4528: Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V Cancer Research. 79: 4528-4528. DOI: 10.1158/1538-7445.Sabcs18-4528 |
0.392 |
|
| 2019 |
Qi Y, Maity TK, Zhang X, Gao S, Roper N, Bahta M, Nguyen K, Cultraro CM, Guha U. Abstract 1438: Integrated proteogenomics utilizing mass spectrometry to identify MHC-associated neopeptides in EGFR mutant lung adenocarcinoma Cancer Research. 79: 1438-1438. DOI: 10.1158/1538-7445.Am2019-1438 |
0.348 |
|
| 2019 |
Kim C, Xi L, Cultraro C, Wei F, Cheng J, Shafiei A, Pham T, Roper N, Akoth E, Strom C, Tu M, Liao W, Chia D, Morris C, Rajan A, et al. P1.01-27 Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC Journal of Thoracic Oncology. 14: S366. DOI: 10.1016/J.Jtho.2019.08.742 |
0.333 |
|
| 2018 |
Kim C, Roper N, Hoang C, Wisch L, Connolly M, Chou H, Wei J, Tyagi M, Cultraro CM, Xi L, Waris M, Nguyen KD, Szabo E, Padiernos E, Kesarwala A, et al. Abstract CT106: Local ablative therapy for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct106 |
0.374 |
|
| 2018 |
Roper N, Gao J, Banday R, Maity T, Zhang X, Venugopalan A, Patidar R, Sindiri S, Cultraro C, Goncearenco A, Panchenko A, Biswas R, Wang J, Hewitt S, Kleiner D, et al. Abstract A182: Apobec-mutagenesis drives mutational heterogeneity while copy number alterations drive transcriptomic and proteogenomic heterogeneity in metastatic lung adenocarcinoma and thymic carcinoma Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A182 |
0.385 |
|
| 2018 |
Kim C, Xi L, Cultraro C, Pham T, Roper N, Bagheri M, Rajan A, Beeler J, Jones G, Raffeld M, Guha U. P1.01-46 Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.602 |
0.407 |
|
| 2017 |
Zhang X, Maity T, Kashyap MK, Bansal M, Venugopalan A, Singh S, Awasthi S, Marimuthu A, Jacob HK, Belkina N, Pitts S, Cultraro CM, Gao S, Kirkali F, Biswas R, et al. Quantitative tyrosine phosphoproteomics of EGFR tyrosine kinase inhibitor-treated lung adenocarcinoma cells reveals potential novel biomarkers of therapeutic response. Molecular & Cellular Proteomics : McP. PMID 28331001 DOI: 10.1074/Mcp.M117.067439 |
0.353 |
|
| 2017 |
Kim C, Roper N, Hoang CD, Szabo E, Connolly M, Padiernos E, Kesarwala AH, Cultraro C, Waris M, Gao S, Steinberg SM, Wong DT, Khan J, Rajan A, Guha U. Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib. Journal of Clinical Oncology. 35: e20545-e20545. DOI: 10.1200/Jco.2017.35.15_Suppl.E20545 |
0.327 |
|
| 2017 |
Roper N, Maity TK, Gao S, Venugopalan AK, Zhang X, Biswas R, Perry S, Cultraro C, Kim C, Hassan R, Thomas A, Rajan A, Kleiner DE, Hewitt SM, Khan J, et al. Rapid/warm autopsy to reveal APOBEC-mutagenesis as driver of heterogeneity of metastatic thoracic tumors. Journal of Clinical Oncology. 35: 9023-9023. DOI: 10.1200/Jco.2017.35.15_Suppl.9023 |
0.357 |
|
| 2017 |
Roper N, Maity TK, Gao J, Venugopalan A, Zhang X, Biswas R, Cultraro C, Kleiner D, Hewitt S, Khan J, Udayan G. Abstract 2927: Proteogenomic heterogeneity in metastatic lung adenocarcinoma revealed from rapid/warm autopsy Cancer Research. 77: 2927-2927. DOI: 10.1158/1538-7445.Am2017-2927 |
0.326 |
|
| 2017 |
Kim C, Roper N, Hoang C, Connolly M, Cultraro C, Szabo E, Waris M, Padiernos E, Kesarwala A, Gao S, Steinberg S, Wong D, Khan J, Rajan A, Guha U. P2.03-052 Local Ablative Therapy for Oligoprogressive, EGFR-Mutant, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib Journal of Thoracic Oncology. 12: S2147. DOI: 10.1016/J.Jtho.2017.09.1303 |
0.377 |
|
| 2017 |
Kesarwala A, Kim C, Jones J, Kaushal A, Roper N, Hoang C, Szabo E, Connolly M, Padiernos E, Cultraro C, Waris M, Gao S, Steinberg S, Khan J, Rajan A, et al. Radiation As a Local Ablative Therapy Option for Oligoprogressive EGFR-Mutant Non-Small Cell Lung Cancer after Treatment with Osimertinib International Journal of Radiation Oncology*Biology*Physics. 99: E467-E468. DOI: 10.1016/J.Ijrobp.2017.06.1719 |
0.359 |
|
| 2016 |
Venugopalan A, Lee MJ, Niu G, Medina-Echeverz J, Tomita Y, Lizak MJ, Cultraro CM, Simpson RM, Chen X, Trepel JB, Guha U. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. Oncotarget. PMID 27494838 DOI: 10.18632/Oncotarget.11021 |
0.393 |
|
| 2015 |
Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, et al. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. Cancer Discovery. 5: 534-49. PMID 25735773 DOI: 10.1158/2159-8290.CD-14-0750 |
0.304 |
|
| 2015 |
Gao S, Cultraro C, BIswas R, Carter CA, Maity TK, Thomas A, Rajan A, Meltzer P, Schrump D, Giaccone G, Khan J, Guha U. Abstract 4759: Whole genome sequencing of sequentially acquired lung and lymph node metastatic sites from a never smoker lung adenocarcinoma patient revealed extensive genomic heterogeneity Cancer Research. 75: 4759-4759. DOI: 10.1158/1538-7445.Am2015-4759 |
0.33 |
|
| 2013 |
Efroni S, Meerzaman D, Schaefer CF, Greenblum S, Soo-Lyu M, Hu Y, Cultraro C, Meshorer E, Buetow KH. Systems analysis utilising pathway interactions identifies sonic hedgehog pathway as a primary biomarker and oncogenic target in hepatocellular carcinoma. Iet Systems Biology. 7: 243-51. PMID 24712101 DOI: 10.1049/Iet-Syb.2010.0078 |
0.335 |
|
| 2013 |
Venugopalan A, Gang N, Guo J, Maity T, Zhang X, Cultraro C, Chen X, Guha U. Abstract 725: In vivo imaging and quantitative proteomics to study responsiveness to EGFR targeted therapy. Cancer Research. 73: 725-725. DOI: 10.1158/1538-7445.Am2013-725 |
0.383 |
|
| 2013 |
Maity TK, Rho H, Belinka N, Xie Z, Zhang X, Venugopalan A, Biswas R, Cultraro C, Zhu H, Guha U. Abstract 5260: Identification of substrates of lung cancer-specific mutant EGFR kinases. Cancer Research. 73: 5260-5260. DOI: 10.1158/1538-7445.Am2013-5260 |
0.397 |
|
| 2012 |
Gegonne A, Tai X, Zhang J, Wu G, Zhu J, Yoshimoto A, Hanson J, Cultraro C, Chen QR, Guinter T, Yang Z, Hathcock K, Singer A, Rodriguez-Canales J, Tessarollo L, et al. The general transcription factor TAF7 is essential for embryonic development but not essential for the survival or differentiation of mature T cells. Molecular and Cellular Biology. 32: 1984-97. PMID 22411629 DOI: 10.1128/Mcb.06305-11 |
0.398 |
|
| 2012 |
Cogliati T, Dunn B, Cultraro C, Hearing L, Segal S. Differential-effects of max proteins (long and short) on growth and differentiation of murine erythroleukemia-cells. Oncology Reports. 1: 179-84. PMID 21607333 DOI: 10.3892/or.1.1.179 |
0.346 |
|
| 2012 |
Cultraro C, Cogliati T, Hearing L, Segal S. Basic mutant Max reverses a c-Myc block to differentiation. Oncology Reports. 3: 141-6. PMID 21594332 DOI: 10.3892/or.3.1.141 |
0.404 |
|
| 2000 |
Barrera-Hernandez G, Cultraro CM, Pianetti S, Segal S. Mad1 function is regulated through elements within the carboxy terminus. Molecular and Cellular Biology. 20: 4253-64. PMID 10825189 DOI: 10.1128/Mcb.20.12.4253-4264.2000 |
0.583 |
|
| 1997 |
Cultraro CM, Bino T, Segal S. Regulated expression and function of the c-Myc antagonist, Mad1, during a molecular switch from proliferation to differentiation. Current Topics in Microbiology and Immunology. 224: 149-58. PMID 9308238 |
0.563 |
|
| 1997 |
Casalini P, Ménard S, Malandrin SM, Rigo CM, Colnaghi MI, Cultraro CM, Segal S. Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression. International Journal of Cancer. 72: 631-6. PMID 9259403 DOI: 10.1002/(Sici)1097-0215(19970807)72:4<631::Aid-Ijc14>3.0.Co;2-E |
0.621 |
|
| 1997 |
Cultraro CM, Bino T, Segal S. Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation. Molecular and Cellular Biology. 17: 2353-9. PMID 9111304 DOI: 10.1128/Mcb.17.5.2353 |
0.635 |
|
| 1996 |
Borrè A, Cultraro CM, Segal S. c-Myc inactivation by mutant Max alters growth and morphology of NCI-H-630 colon cancer cells. Journal of Cellular Physiology. 169: 200-8. PMID 8841436 DOI: 10.1002/(Sici)1097-4652(199610)169:1<200::Aid-Jcp20>3.0.Co;2-F |
0.636 |
|
| 1994 |
Dunn BK, Cogliati T, Cultraro CM, Bar-Ner M, Segal S. Regulation of murine Max (Myn) parallels the regulation of c-Myc in differentiating murine erythroleukemia cells. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 5: 847-54. PMID 7986749 |
0.567 |
|
| 1993 |
Cogliati T, Dunn BK, Bar-Ner M, Cultraro CM, Segal S. Transfected wild-type and mutant max regulate cell growth and differentiation of murine erythroleukemia cells. Oncogene. 8: 1263-8. PMID 8479748 |
0.627 |
|
| 1992 |
Bar-Ner M, Messing LT, Cultraro CM, Birrer MJ, Segal S. Regions within the c-Myc protein that are necessary for transformation are also required for inhibition of differentiation of murine erythroleukemia cells. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 3: 183-90. PMID 1633109 |
0.609 |
|
| Show low-probability matches. |